Exelixis Inc. (NASDAQ: EXEL) entered into a clinical development collaboration with Merck to conduct STELLAR-316, a phase 3 trial testing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE